$OKUR
OnKure Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024123233 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $904.0K
YoY Change -93.36%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.664M
YoY Change -77.67%
Operating Profit -$4.664M
YoY Change -77.67%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $972.0K
YoY Change -42.55%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$3.692M
YoY Change -80.77%
Net Earnings / Revenue
Basic Earnings Per Share -$1.10
Diluted Earnings Per Share -$1.10
COMMON SHARES
Basic Shares Outstanding 33.43M
Diluted Shares Outstanding 3.343M

Balance Sheet

Concept 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $60.69M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $77.00M
YoY Change -40.21%
LONG-TERM ASSETS
Property, Plant & Equipment $59.00K
YoY Change -88.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $147.0K
YoY Change 81.48%
Total Long-Term Assets $646.0K
YoY Change -60.02%
TOTAL ASSETS
Total Short-Term Assets $77.00M
Total Long-Term Assets $646.0K
Total Assets $77.65M
YoY Change -40.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $237.0K
YoY Change -90.42%
Accrued Expenses $725.0K
YoY Change -93.27%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.248M
YoY Change -76.05%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.248M
Total Long-Term Liabilities
Total Liabilities $3.627M
YoY Change -76.52%
SHAREHOLDERS EQUITY
Retained Earnings -$236.0M
YoY Change 23.86%
Common Stock $0.00
YoY Change -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $74.02M
YoY Change
Total Liabilities & Shareholders Equity $77.65M
YoY Change -40.45%

Cashflow Statement

Concept 2024 Q3
OPERATING ACTIVITIES
Net Income -$3.692M
YoY Change -80.77%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
331000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3248000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18177000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
379000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
642000
CY2024Q3 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
0
CY2023Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
7000
CY2024Q3 us-gaap Liabilities
Liabilities
3627000
CY2023Q4 us-gaap Liabilities
Liabilities
18826000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3343525
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3343525
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3342034
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3342034
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
309969000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
307076000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-235953000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-218474000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
74018000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
88610000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
77645000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
107436000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
904000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13622000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6436000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39009000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3760000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7266000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14155000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19038000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
4664000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
20888000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001637715
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40315
dei Entity Registrant Name
EntityRegistrantName
ONKURE THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2309515
dei Entity Address Address Line1
EntityAddressAddressLine1
6707 Winchester Circle, Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
Boulder
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80301
dei City Area Code
CityAreaCode
720
dei Local Phone Number
LocalPhoneNumber
307-2892
dei Security12b Title
Security12bTitle
Class A Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
OKUR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60689000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27632000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
15979000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
75331000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
331000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3659000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
76999000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
106622000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
59000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
134000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
440000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
599000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
147000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
81000
CY2024Q3 us-gaap Assets
Assets
77645000
CY2023Q4 us-gaap Assets
Assets
107436000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
237000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8717000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
725000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9129000
CY2024Q3 okur Private Placement Deposit
PrivatePlacementDeposit
2000000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
286000
us-gaap Operating Expenses
OperatingExpenses
20591000
us-gaap Operating Expenses
OperatingExpenses
58047000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4664000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20888000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20591000
us-gaap Operating Income Loss
OperatingIncomeLoss
-58047000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
972000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1692000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3112000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4213000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3692000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-19196000
us-gaap Net Income Loss
NetIncomeLoss
-17479000
us-gaap Net Income Loss
NetIncomeLoss
-53834000
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
15000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
10000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-6000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
22000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3677000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19186000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17485000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53812000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.1
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.1
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.68
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-18.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-18.11
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3342824
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3342824
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3380794
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3380794
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3343287
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3343287
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2971868
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2971868
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
88610000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1078000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-20000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8426000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
81242000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
989000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5361000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
76869000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
826000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
15000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3692000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
74018000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
99970000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1157000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
55000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-15107000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
87084000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1207000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
282000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-43000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-19531000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
132528000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
173000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
10000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-19196000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
114944000
us-gaap Net Income Loss
NetIncomeLoss
-17479000
us-gaap Net Income Loss
NetIncomeLoss
-53834000
us-gaap Share Based Compensation
ShareBasedCompensation
2893000
us-gaap Share Based Compensation
ShareBasedCompensation
3793000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
40000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
126000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1904000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3551000
okur Fair Value Changes Of Share Based Performance Award
FairValueChangesOfShareBasedPerformanceAward
-7000
okur Fair Value Changes Of Share Based Performance Award
FairValueChangesOfShareBasedPerformanceAward
1040000
okur Non Cash Lease Expense
NonCashLeaseExpense
128000
okur Non Cash Lease Expense
NonCashLeaseExpense
354000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-37000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-5000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3351000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2025000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-16884000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6507000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-277000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-394000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30102000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43929000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
196000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
67750000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
190058000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
129000000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
161000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
61248000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29254000
okur Private Placement Deposit In Advance Of The Closing
PrivatePlacementDepositInAdvanceOfTheClosing
2000000
us-gaap Payments For Repurchase Of Private Placement
PaymentsForRepurchaseOfPrivatePlacement
89000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
455000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1911000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64993000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
33057000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8190000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27632000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19927000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60689000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11737000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
11000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
76700000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
496787
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
653730
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
15976000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
15978000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
75324000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
75331000
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2024Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q4 okur Accrued Clinical And Regulatory Expenses
AccruedClinicalAndRegulatoryExpenses
3661000
CY2023Q4 okur Accrued Manufacturing Expense
AccruedManufacturingExpense
1100000
CY2024Q3 okur Accrued Compensation Expense
AccruedCompensationExpense
361000
CY2023Q4 okur Accrued Compensation Expense
AccruedCompensationExpense
3948000
CY2024Q3 okur Accrued Other
AccruedOther
364000
CY2023Q4 okur Accrued Other
AccruedOther
420000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
725000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9129000
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M6D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M18D
us-gaap Operating Lease Payments
OperatingLeasePayments
291000
us-gaap Operating Lease Payments
OperatingLeasePayments
397000
us-gaap Operating Lease Expense
OperatingLeaseExpense
214000
us-gaap Operating Lease Expense
OperatingLeaseExpense
338000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
98000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
371000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
285000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
754000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
89000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
665000
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1017162
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
530125
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
47.6
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
62996
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
49.05
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
467129
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
47.39
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M18D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
360725
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
50.2
okur Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P6Y3M18D
okur Share Based Compensation Arrangement By Share Based Payment Award Options Vested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
368048
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
50.17
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q3 okur Performance Awards Liability
PerformanceAwardsLiability
0
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
826000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1429000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2893000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3793000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-123233-index-headers.html Edgar Link pending
0000950170-24-123233-index.html Edgar Link pending
0000950170-24-123233.txt Edgar Link pending
0000950170-24-123233-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
okur-20240930.htm Edgar Link pending
okur-20240930.xsd Edgar Link pending
okur-ex31_1.htm Edgar Link pending
okur-ex31_2.htm Edgar Link pending
okur-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
okur-20240930_htm.xml Edgar Link completed
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending